PharmaCyte Biotech, Inc.

- 18 SEP 2014
Nuvilex Updates Shareholders on Recent Activities and Discusses Future Plans for Development of Treatments for Cancer and Diabetes
SILVER SPRING, MD, September 18, 2014 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today provides its shareholders with an update on recent activities of PharmaCyte Biotech and outlines future plans for the development of treatments in the areas of
Read more →
- Posted in
- News
- 02 SEP 2014
Nuvilex Submits Application for Orphan Drug Designation to the European Medicines Agency for Its Cell-in-a-Box(R) Treatment for Pancreatic Cancer
SILVER SPRING, Md., Sept. 2, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has submitted an application to the European Medicines Agency (EMA) for an Orphan Drug Designation for its Cell-in-a-Box(R) treatment for pancreatic cancer.
Read more →
- Posted in
- News
- 20 AUG 2014
Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex’s Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid
SILVER SPRING, Md., Aug. 20, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development’s (TD2) facilities in Scottsdale, Arizona, to determine if PharmaCyte Biotech’s unique cancer treatment can slow the
Read more →
- Posted in
- News
- 14 AUG 2014
Nuvilex Announces Publication of Combined Results of the Initial Phase 1/2 Clinical Trial and a Second Phase 2 Clinical Trial of the Cell-in-a-Box(R) Plus Ifosfamide Combination in Patients With Advanced, Inoperable Pancreatic Cancer
SILVER SPRING, Md., Aug. 14, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its partner, Austrianova, has reported the results from the second Phase 2 clinical trial combining the Cell-in-a-Box(R) cellulose-based live cell encapsulation technology plus
Read more →
- Posted in
- News
- 13 AUG 2014
Nuvilex Provides Update on Status of Preclinical Studies at Translational Drug Development
SILVER SPRING, Md., Aug. 13, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it is providing shareholders with an update on the status of PharmaCyte Biotech’s preclinical studies to be conducted by Translational Drug Development (TD2)
Read more →
- Posted in
- News
- 04 AUG 2014
Nuvilex Announces That Dr. Richard M. Hyslop Will Present at the ACS Annual Meeting on “Sustainable, Green Chemistry and Medicine: Targeted Cannabinoid-Based Chemotherapy Utilizing Cell-in-a-Box(R) Live Cell Encapsulation Technology.”
SILVER SPRING, Md., Aug. 4, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Dr. Richard M. Hyslop, Professor of Chemistry and Biochemistry at the University of Northern Colorado (UNC) and member of the Scientific Advisory Board
Read more →
- Posted in
- News
- 26 JUL 2014
Can pot fight cancer? UNC seeks the answer
GREELEY – The University of Northern Colorado is one of the first schools in the state to begin investigating the cancer-fighting properties of marijuana, using a new partnership with biotechnology company PharmaCyte Biotech. Silver Springs, Md.-based PharmaCyte Biotech (OTCQB: NVLX) launched the research project with UNC in May. Its goal is to determine whether the
Read more →
- Posted in
- News
- 17 JUL 2014
Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs with Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyclophosphamide
SILVER SPRING, Md., July 17, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced, in cooperation with its partner Austrianova, the results of a veterinary Phase I/II clinical trial in dogs with mammary tumors who were treated with
Read more →
- Posted in
- News
- 09 JUL 2014
Preparations for Preclinical Studies on the Effect of PharmaCyte Biotech’s Pancreatic Cancer Treatment on Ascites Fluid Accumulation Completed
SILVER SPRING, Md., July 9, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that all preparations for the commencement of its preclinical studies to determine the effectiveness of PharmaCyte Biotech’s pancreatic cancer treatment in slowing down the
Read more →
- Posted in
- News
- 01 JUL 2014
Nuvilex Executives Attend 2014 BIO International Convention
SILVER SPRING, Md., July 1, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Chief Executive Officer and President Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree attended the 2014 BIO International Convention held
Read more →
- Posted in
- News

Press Releases